See behind – go beyond

We believe that extraordinary things emerge through the blending of knowledge, courage and responsibility.

MLL Münchner Leukämielabor GmbH



6 areas. 1 diagnosis.



Munich Leukemia Laboratory (MLL) is active nationally and internationally in the field of diagnosing hematological diseases. The company's high level of technical expertise, quality assurance and rapid turnaround guarantee optimal testing procedures when questions arise in this area. Its modern inventory of equipment and its scientifically state-of-the-art analytical methods make for the best possible diagnostics. Münchner Leukämielabor is one of the world's leading companies when it comes to the wide range of its diagnostics portfolio. The combination of the interrelated methods of cytomorphology, chromosome band analysis, FISH, immunophenotyping, and a wide variety of molecular genetic testing procedures such as NGS and the possibility of sequencing entire genomes make it possible to prepare a comprehensive picture of an existing illness to ensure that the right customized medical treatment can be provided to a patient.



New business fields

MLLi: using technology to shape the future

In order to be ideally positioned for the future, Munich Leukemia Laboratory founded an affiliate company focused on technology. MLLi (i = innovation) is specialized in the digital processing of data from leukemia diagnostics. Among other things, MLLi offers web-based tools to provide interpretations of data for the diagnosis of hematological neoplasias.

MLL Dx: international laboratory expertise

MLL Dx (Dx = diagnostics) conducts laboratory analyses – especially for its industrial and international business partners in the hematological field – and provides expertise for diagnostic laboratories on the international scene.

Our values

Knowledge, courage and responsibility

We are a leading institution in the area of leukemia diagnostics and research, operating within a highly innovative environment. Our aim is to shape the future of hematological diagnostics and therapy through the use of state-of-the-art molecular and IT-supported methods.

We possess the knowledge to accomplish extraordinary things.

We are experts. Our findings are reliable and in line with the latest insights – thanks to diagnostics by an interdisciplinary team with a comprehensive scientific background and decades of experience as practicing hematologists, geneticists and bioinformatics specialists.

We have the courage to push boundaries.

As committed go-getters, we are thirsty for knowledge, energetic and ambitious. We question the status quo, building on current standards to develop game-changing methods. State-of-the-art technology helps us to continue optimizing diagnostics.

We have the inner drive to seize responsibility.

We are doctors, scientists, advisers, counsellors – and humans. At the heart of our work is the responsibility we accept for patients suffering from leukemia or lymphoma: We know that there is a personal story behind every sample. This motivates us to proceed with great care. Our optimized diagnoses based on an extensive spectrum of methods help to extend life expectancy with improved quality of life.

Quick results.

Cytomorphology — **2-24 h**

Immuno-phenotyping — **2-24 h**

Chromosome analysis — **3-7 days**

Chromosome analysis, incl. 24-color FISH (5-10 days)

Fluorescence in situ hybridization — **1-3 days**

Molecular genetics — **4 h - 10 days**

- Sequencing (3-10 days)
- Quantitative PCR (1-5 days)
- PCR detection for fusion genes (1-5 days)
- *PML-RARA* clarification with diagnosis (4-6 h)
- B/T-cell receptor analysis, chimerism analysis (3-10 days)

We use an interdisciplinary approach. Individual specialty areas work closely together in order to provide our clients with a reliable diagnosis. That is why many of the samples are run through various diagnostic methods. Always at the heart of our work is our responsibility towards our patients.

Sharing knowledge.

Advancing science.

We are scientists and doctors. We engage in a large number of scientific projects and international collaborations that contribute to the advancement of knowledge in the diagnosis and prognosis of leukemias and lymphomas. Moreover, we promptly develop and implement the latest technical innovations, including test procedures, devices and individual tests. In doing this, we are significant drivers of progress in the field of hematological laboratory diagnostics.



Interdisciplinary and international research.

Besides routine diagnostics with a rapid turnaround, MLL also focuses on applied research for leukemia diagnostics. We believe that our central task is to encourage discussion of our knowledge, data and findings and to place them at the disposal of the scientific community in talks, training and publications. We have contributed to a broad variety of collaborations on scientific issues within hematology for more than 20 years, especially through our international networks with other diagnostic laboratories and research groups around the world.



Overview of our publications by year (2008 - 2018)

5,000 genome project

Knowledge opens up opportunities.

Our vision is to obtain an even better understanding of the basic genetic principles of the various types of leukemia and lymphoma and to grasp the complexity behind each illness. It is only by doing so that we will be able to offer each patient the best possible diagnostics in the future.



This is the reason why the 5,000 genome project was launched at MLL. In order to gain as much knowledge as possible, we have begun to examine a diverse range of leukemia and lymphoma sub-groups in our project. Using our Biobank, we also have the ability to include rare forms of leukemia and lymphoma, thereby covering a very wide spectrum of entities. We take advantage of the options offered by high-throughput sequencing and examine both the genome (WGS, whole-genome sequencing) as well as the transcriptome (RNA-Seq) of a patient in order to obtain as much genetic information as possible. Via the combination of WGS and RNA-Seq, we validate not only the variants found on both levels, but also pursue the question of whether the mutations found are transcribed and expressed and/or whether the translocations found also lead to a fusion transcript. Furthermore, we attempt to correlate the genotype with the expression profile in order to find out more about genetic changes and their impact on the cell.

Contact us!

MLL Münchner Leukämielabor GmbH

Max-Lebsche-Platz 31
81377 München
T: +49 (0)89 99017-0
F: +49 (0)89 99017-111

info@mll.com
www.mll.com